CHEMOCENTRYX INC's ticker is CCXI and the CUSIP is 16383L106. A total of 165 filers reported holding CHEMOCENTRYX INC in Q1 2020. The put-call ratio across all filers is 0.52 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $1,291,000 | +85.8% | 24,993 | -10.9% | 0.08% | +127.0% |
| Q2 2022 | $695,000 | +19.4% | 28,037 | +20.8% | 0.04% | +19.4% |
| Q1 2022 | $582,000 | -54.4% | 23,210 | -33.7% | 0.03% | -59.7% |
| Q4 2021 | $1,275,000 | +414.1% | 35,031 | +141.5% | 0.08% | +450.0% |
| Q3 2021 | $248,000 | -47.8% | 14,503 | -59.1% | 0.01% | -46.2% |
| Q2 2021 | $475,000 | -41.7% | 35,493 | +123.2% | 0.03% | -43.5% |
| Q1 2021 | $815,000 | -19.2% | 15,904 | -2.4% | 0.05% | -37.0% |
| Q4 2020 | $1,009,000 | -72.8% | 16,301 | -75.9% | 0.07% | -39.7% |
| Q3 2020 | $3,711,000 | +1193.0% | 67,721 | +1255.8% | 0.12% | +1628.6% |
| Q2 2020 | $287,000 | -61.0% | 4,995 | -72.7% | 0.01% | -63.2% |
| Q1 2020 | $736,000 | -78.6% | 18,315 | -78.9% | 0.02% | -60.4% |
| Q4 2019 | $3,439,000 | +3175.2% | 86,948 | +463.2% | 0.05% | +4700.0% |
| Q3 2019 | $105,000 | -40.3% | 15,439 | +21.8% | 0.00% | -75.0% |
| Q1 2019 | $176,000 | – | 12,677 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tri Locum Partners LP | 276,400 | $4,726,000 | 1.88% |
| TANG CAPITAL MANAGEMENT LLC | 500,000 | $8,550,000 | 1.78% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 94,300 | $7,131,000 | 1.72% |
| Integral Health Asset Management, LLC | 300,000 | $5,130,000 | 1.48% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 139,200 | $2,380,000 | 1.35% |
| MANGROVE PARTNERS IM, LLC | 686,300 | $11,736,000 | 1.05% |
| Ikarian Capital, LLC | 600,000 | $10,261,000 | 0.72% |
| Ikarian Capital, LLC | 600,000 | $10,260,000 | 0.72% |
| Sofinnova Investments, Inc. | 517,708 | $8,853,000 | 0.52% |
| Birchview Capital, LP | 25,000 | $428,000 | 0.29% |